LncRNAs KB‑1836B5, LINC00566 and FAM27L are associated with the survival time of patients with ovarian cancer

Li,Huijian; Gong,Mi; Zhao,Min; Wang,Xinru; Cheng,Wenjun; Xia,Yankai

doi:10.3892/ol.2018.9143

LncRNAs KB‑1836B5, LINC00566 and FAM27L are associated with the survival time of patients with ovarian cancer

Authors:
- Huijian Li
- Mi Gong
- Min Zhao
- Xinru Wang
- Wenjun Cheng
- Yankai Xia
View Affiliations

Affiliations: Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Gynecology, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, Jiangsu 214002, P.R. China, State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China, State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China
Published online on: July 12, 2018 https://doi.org/10.3892/ol.2018.9143
Pages: 3735-3745
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OvCa) is the most common gynecological malignancy type in the United States in 2014. Functions of long non‑coding RNAs (lncRNAs) in OvCa have attracted increasing attention from researchers. The present study aimed to identify an lncRNA‑based signature for survival prediction in patients with OvCa. On the basis of lncRNA expression profiles from The Cancer Genome Atlas data portal, differentially expressed lncRNAs (DELs) were selected from patients with good prognosis and poor prognosis in the training set, from which the prognostic lncRNAs were identified using univariate and multivariate Cox regression analyses and used to construct a risk scoring system. The prognostic power of this lncRNA signature was tested in the training set and validated in validation dataset and entire dataset. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the genes significantly associated with ≥1 prognostic lncRNA, and a total of 112 DELs were identified. LncRNAs KB‑1836B5, long intergenic non‑protein coding RNA 566 (LINC00566) and family with sequence similarity E5 (FAM27L) were determined to be prognostic lncRNAs. A three‑lncRNAs signature‑based risk scoring system was developed, which classified the patients from the training set into high‑risk and low‑risk groups with significantly different overall survival time. Risk stratification capability of the three‑lncRNAs signature was validated in the validation and entire set. Multivariate Cox regression and data stratification analyses determined that the three‑lncRNAs signature was independent of other clinical variables. GO and KEGG pathway enrichment analyses determined that the three prognostic lncRNAs may be involved in a number of metabolic processes and signaling pathways, including the mechanistic target of rapamycin signaling pathway, ubiquitin‑mediated proteolysis, and complement and coagulation cascades pathways. In conclusion, the results of the present study demonstrated that the three‑lncRNAs signature may be an independent biomarker for predicting prognosis in patients with OvCa.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. Ca A Cancer J Clin. 65:5–29. 2014. View Article : Google Scholar
2	Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR and Seamon LG: Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 120:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
3	Dey BK, Mueller AC and Dutta A: Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription. 5:e9440142014. View Article : Google Scholar : PubMed/NCBI
4	Yang G, Lu X and Yuan L: LncRNA: A link between RNA and cancer. Biochim Biophys Acta (BBA)-Gene Regul Mech. 1839:1097–1109. 2014. View Article : Google Scholar
5	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:12532015. View Article : Google Scholar : PubMed/NCBI
6	Ren C, Li X, Wang T, Zhao C, Liang T, Zhu Y, Li M, Yang C, Zhao Y and Zhang GM: Functions and mechanisms of long noncoding RNAs in ovarian cancer. Int J Gynecol Cancer. 25:566–569. 2015. View Article : Google Scholar : PubMed/NCBI
7	Cheng Z, Guo J, Chen L, Luo N, Yang W and Qu X: A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Oncotarget. 6:25381–25389. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yim GW, Kim HJ, Kim LK, Kim SW, Kim S, Nam EJ and Kim YT: Long non-coding RNA HOXA11 antisense promotes cell proliferation and invasion and predicts patient prognosis in serous ovarian cancer. Cancer Res Treat. 49:656–668. 2016. View Article : Google Scholar : PubMed/NCBI
9	Chen ZJ, Zhang Z, Xie BB and Zhang HY: Clinical significance of up-regulated lncRNA NEAT1 in prognosis of ovarian cancer. Eur Rev Med Pharmacol Sci. 20:3373–3377. 2016.PubMed/NCBI
10	Zhou M, Wang X, Shi H, Cheng L, Wang Z, Zhao H, Yang L and Sun J: Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget. 7:12598–12611. 2016.PubMed/NCBI
11	Bristow RE, Palis BE, Chi DS and Cliby WA: The national cancer database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 118:262–267. 2010. View Article : Google Scholar : PubMed/NCBI
12	Anders S and Huber W: Differential expression of RNA-Seq data at the gene level-the DESeq package. Embl. 2012.
13	Robinson MD, Mccarthy DJ and Smyth GK: edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
14	Wang P, Wang Y, Bo H, Zou X and Mao JH: A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 7:55343–55351. 2016.PubMed/NCBI
15	Hanley JA: The robustness of the ‘binormal’ assumptions used in fitting ROC curves. Med Decis Making. 8:197–203. 1988. View Article : Google Scholar : PubMed/NCBI
16	Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID bioinformatics resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35:169–175. 2007. View Article : Google Scholar
17	Consortium GO: Gene ontology consortium: Going forward. Nucleic Acids Res. 43:1049–1056. 2015. View Article : Google Scholar
18	Minoru K, Yoko S, Masayuki K, Miho F and Mao T: KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44:457–462. 2016. View Article : Google Scholar
19	Qi L, Liu C, Yuan X, Kang S, Miao R, Xiao H, Zhao G, Luo H, Bu D, Zhao H, et al: Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. Nucleic Acids Res. 39:3864–3878. 2011. View Article : Google Scholar : PubMed/NCBI
20	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
21	Nina H and Damjan G: Long non-coding RNA in cancer. Int J Mol Sci. 14:4655–4669. 2013. View Article : Google Scholar : PubMed/NCBI
22	Rooth C: Ovarian cancer: Risk factors, treatment and management. Br J Nurs. 22:S23–S30. 2013. View Article : Google Scholar : PubMed/NCBI
23	Hunn J and Rodriguez GC: Ovarian cancer: Etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 55:3–23. 2012. View Article : Google Scholar : PubMed/NCBI
24	Fatica A and Bozzoni I: Long non-coding RNAs: New players in cell differentiation and development. Nature Rev Genet. 15:7–21. 2014. View Article : Google Scholar : PubMed/NCBI
25	Kornienko AE, Guenzl PM, Barlow DP and Pauler FM: Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 11:592013. View Article : Google Scholar : PubMed/NCBI
26	Dello Russo C, Lisi L, Feinstein DL and Navarra P: mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis. Glia. 61:301–311. 2013. View Article : Google Scholar : PubMed/NCBI
27	Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
28	Laplante M and Sabatini DM: mTOR signaling at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
29	Mabuchi S, Kuroda H, Takahashi R and Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
30	Li H, Zeng J and Shen K: PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
31	Dobbin ZC and Landen CN: The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
32	Bassermann F, Eichner R and Pagano M: The ubiquitin proteasome system-implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 1843:150–162. 2014. View Article : Google Scholar : PubMed/NCBI
33	Johnson DE: The ubiquitin-proteasome system: Opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 22:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
34	Varela JC and Tomlinson S: Complement: An overview for the clinician. Hematol Oncol Clin North Am. 29:409–427. 2015. View Article : Google Scholar : PubMed/NCBI
35	Afshar-Kharghan V: The role of the complement system in cancer. J Clin Invest. 127:780–789. 2017. View Article : Google Scholar : PubMed/NCBI
36	Pio R, Corrales L and Lambris JD: The role of complement in tumor growth. Tumor Microenviron Cell Stress. 229–262. 2013.